info@birdgroup.be

Login

Research papers

Clin Gastroenterol Hepatol . 2025 Feb;23(2):341-350.e6. doi: 10.1016/j.cgh.2024.07.010. Epub 2024 Jul 31.
Endoscopic, Histologic, and Composite Endpoints in Patients With Ulcerative Colitis Treated With Etrasimod

The Lancet, Volume 404, Issue 10470, 2423 - 2436
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease

The Lancet Gastroenterology & Hepatology, online November 18, 2024, https://doi.org/10.1016/S2468-1253(24)00317-0
Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial

Journal of Crohn's and Colitis, Volume 18, Issue Supplement_2, October 2024, Pages ii55–ii66
Framework of IBD Care Delivery Across Ages

Gastroenterology, Volume 166, Issue 3, 521 - 532
AGA Clinical Practice Update on Diet and Nutritional Therapies in Patients With Inflammatory Bowel Disease: Expert Review

Gastroenterology. 2024 Jun;166(6):949-956. doi: 10.1053/j.gastro.2024.02.016. Epub 2024 Feb 18. PMID: 38378092.
Commentary on the Epidemiology of Inflammatory Bowel Disease in Compounding Prevalence Nations: Toward Sustaining Healthcare Delivery

N Engl J Med . 2024 Jul 18;391(3):213-223. doi: 10.1056/NEJMoa2314585.
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease

Lancet Gastroenterol Hepatol. 2024 June vol 9, issue 6, p521-538
Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study

1
2
3
4
›